Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Receptors, Androgen”

216 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 216 results

Testing effectiveness (Phase 2)Looking for participantsNCT07223385
What this trial is testing

High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)

Who this might be right for
Prostate Cancer (Diagnosis)Prostate Cancer Stage IVCV Risk
Cedars-Sinai Medical Center 80
Testing effectiveness (Phase 2)Ended earlyNCT02489123
What this trial is testing

Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Who this might be right for
Ann Arbor Stage I Mantle Cell LymphomaAnn Arbor Stage II Mantle Cell LymphomaAnn Arbor Stage III Mantle Cell Lymphoma+3 more
University of Washington 8
Testing effectiveness (Phase 2)Looking for participantsNCT07336446
What this trial is testing

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

Who this might be right for
Prostate Cancer
AstraZeneca 300
Testing effectiveness (Phase 2)Ended earlyNCT00861471
What this trial is testing

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

Who this might be right for
Prostate CancerProstatic Neoplasms
NYU Langone Health 24
Testing effectiveness (Phase 2)Ended earlyNCT03531827
What this trial is testing

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Who this might be right for
Metastatic Castration Resistant Prostate CancerProstate Neoplasms
National Cancer Institute (NCI) 4
Not applicableStudy completedNCT05404334
What this trial is testing

Of Androgen Receptor Expression in Breast Cancer With or Without BRCA Mutation

Who this might be right for
Breast Cancer
Banaras Hindu University 231
Testing effectiveness (Phase 2)Study completedNCT05694819
What this trial is testing

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Who this might be right for
Salivary Gland Cancer
National Cancer Center Hospital East 57
Testing effectiveness (Phase 2)Ended earlyNCT03600467
What this trial is testing

Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma

Who this might be right for
Solid TumorAndrogen Receptor Gene Overexpression
St Vincent's Hospital, Sydney 4
Very early researchStudy completedNCT02420977
What this trial is testing

Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer

Who this might be right for
Advanced Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 23
Large-scale testing (Phase 3)Active Not RecruitingNCT04720157
What this trial is testing

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Prostatic Neoplasms
Novartis Pharmaceuticals 1,140
Not applicableStudy completedNCT07086651
What this trial is testing

Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer (mCSPC)Cancer of the ProstateProstate Neoplasms+1 more
Pfizer 1,300
Very early researchActive Not RecruitingNCT05683964
What this trial is testing

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

Who this might be right for
Prostate AdenocarcinomaProstate CancerMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Beth Israel Deaconess Medical Center 9
Not applicableStudy completedNCT03938766
What this trial is testing

Upregulation of PSMA Receptors After Androgen Deprivation Therapy on PSMA PET/CT Imaging in Prostate Cancer

Who this might be right for
Prostate Cancer
Jewish General Hospital 2
Not applicableStudy completedNCT02434562
What this trial is testing

Development and Validation of in Vitro Cell-based Bioassays for Nuclear Receptor Activation

Who this might be right for
HypogonadismEstrogensTestosterone+1 more
Universitaire Ziekenhuizen KU Leuven 73
Testing effectiveness (Phase 2)Study completedNCT01942837
What this trial is testing

Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute 67
Early research (Phase 1)Study completedNCT03207529
What this trial is testing

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Who this might be right for
Advanced Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+15 more
M.D. Anderson Cancer Center 18
Not applicableStudy completedNCT05612880
What this trial is testing

Physical Function During ARSI Treatment

Who this might be right for
Advanced Prostate Carcinoma
UNC Lineberger Comprehensive Cancer Center 24
Testing effectiveness (Phase 2)Study completedNCT03359473
What this trial is testing

Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)

Who this might be right for
Cachexia
GlaxoSmithKline 97
Testing effectiveness (Phase 2)Ended earlyNCT02000375
What this trial is testing

A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)

Who this might be right for
Metastatic BreastcancerEstrogen Receptor Positive Breast CancerEstrogen Receptor Negative Neoplasm+3 more
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 20
Testing effectiveness (Phase 2)Ended earlyNCT02067741
What this trial is testing

CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer

Who this might be right for
Metastatic Breast AdenocarcinomaBreast Cancer
Swiss Cancer Institute 29
Next Page